AustraliaHealth

Telix Pharmaceuticals (ASX:TLX) logged an 11% quarter-over-quarter increase in group revenue to US$230 million for the period ended March 31.

Medical technology firm ImpediMed (ASX:IPD) appointed Erik Anderson as Managing Director and CEO, effective April 7.

Mesoblast (ASX:MSB) announced that net sales for its flagship product, Ryoncil, reached US$30.3 million for the quarter ended March 31.

Amplia Therapeutics (ASX:ATX) announced a shift in its clinical programme, halting further recruitment for the AMPLICITY trial.

AFT Pharmaceuticals (ASX:AFP) recorded sustained double-digit sales growth across its entire global portfolio for the March quarter of 2026.

Paradigm Biopharmaceuticals (ASX:PAR) announced a strategic research collaboration with City St George's, University of London.

Vitura Health (ASX:VIT) announced the appointment of Justin James as its new CEO.

Emyria (ASX:EMD) has launched a targeted clinical workforce recruitment campaign in New South Wales.

Pathkey.AI (ASX:PKY) has executed a strategic services agreement with Imunexus Therapeutics.

Healthscope remains current with its financial obligations, having paid 100% of all rent due across its hospital portfolio up to and including April..

Bioxyne (ASX:BXN) announced a strategic manufacturing agreement with the Canadian-based industry giant, Aurora Cannabis.

Lumos Diagnostics (ASX:LDX) announced its largest purchase order to date for its flagship FebriDx rapid point-of-care test.